重庆发文:10项医药创新任务限期完成

2019-03-29 佚名 药智网

3月27日,重庆市人民政府发布了《关于贯彻落实国务院支持自由贸易试验区深化改革创新若干措施的通知》,同时发布了附件《重庆市贯彻落实国务院支持自贸试验区深化改革创新措施任务分工》,其中涉及医药的改革创新措施任务共有10项,要求限期完成。 卫生健康行政部门对自贸试验区内的社会办医疗机构配置乙类大型医用设备实行告知承诺制。2019年6月底前完成。


3月27日,重庆市人民政府发布了《关于贯彻落实国务院支持自由贸易试验区深化改革创新若干措施的通知》,同时发布了附件《重庆市贯彻落实国务院支持自贸试验区深化改革创新措施任务分工》,其中涉及医药的改革创新措施任务共有10项,要求限期完成。

卫生健康行政部门对自贸试验区内的社会办医疗机构配置乙类大型医用设备实行告知承诺制。2019年6月底前完成。

执行《重庆市乙类大型医用设备配置许可管理实施细则(试行)》。

对自贸试验区内,申请单位为筹建或在建的,承诺在大型医用设备投入使用前,具备相应技术条件、配套设施和专业技术人员资质、能力的,对其申请配置乙类大型医用设备予以批准。

自贸试验区内医疗机构可根据自身的技术能力,按照有关规定开展干细胞临床前沿医疗技术研究项目。2019年6月底前完成。

支持自贸试验区内符合条件的医疗机构申请国家干细胞临床研究机构资质。

支持已获得国家干细胞临床研究资质的医疗机构开展干细胞临床研究项目。

支持设立首次进口药品和生物制品口岸。2019年9月底前完成。

争取增设生物制品进口功能尽快落地。

做好首次进口药品通关及检验相关准备工作,研究制定增设首次进口药品功能口岸的相关条件和标准,全力做好对接和落地工作。

按照《药品进口管理办法》《出入境特殊物品管理规定》等,对首次入境药品和生物制品进行严格监管。

鼓励在吸纳非卫生技术人员在医疗机构提供中医治未病服务、医疗机构中医治未病专职医师职称晋升、中医治未病服务项目收费等方面先行试点。2019年6月底前完成。

进一步明确吸纳非卫生技术人员在医疗机构提供非诊疗性中医治未病的具体条件。

向国家卫生健康委争取将中医治未病纳入职称考试专业目录。

自贸试验区内公立医院中医治未病服务项目收费按照《重庆市医疗服务价格》执行,非营利性民营医疗机构参照执行,营利性医疗机构自行确定服务项目收费标准。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1997712, encodeId=345a199e712bd, content=<a href='/topic/show?id=d8d85803457' target=_blank style='color:#2F92EE;'>#新任务#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58034, encryptionId=d8d85803457, topicName=新任务)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c950224, createdName=hjwang79, createdTime=Wed Apr 10 10:14:00 CST 2019, time=2019-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022692, encodeId=a76b2022692a3, content=<a href='/topic/show?id=834735289ed' target=_blank style='color:#2F92EE;'>#医药创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35289, encryptionId=834735289ed, topicName=医药创新)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Fri Sep 27 07:14:00 CST 2019, time=2019-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285725, encodeId=0ea21285e2576, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Mar 30 16:14:00 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409825, encodeId=7d6e140982531, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Mar 30 16:14:00 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363732, encodeId=097b363e322e, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRkia1DP5MpwEgtXo1XhXA11xD6MWKxunAZFXKSNic0fWHUQx83oNHPlRMxxIctM83QKeCLkJpMibibiaC/0, createdBy=7e581734408, createdName=深海的鱼, createdTime=Fri Mar 29 06:48:25 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363730, encodeId=c6b6363e30b2, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Fri Mar 29 06:09:26 CST 2019, time=2019-03-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1997712, encodeId=345a199e712bd, content=<a href='/topic/show?id=d8d85803457' target=_blank style='color:#2F92EE;'>#新任务#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58034, encryptionId=d8d85803457, topicName=新任务)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c950224, createdName=hjwang79, createdTime=Wed Apr 10 10:14:00 CST 2019, time=2019-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022692, encodeId=a76b2022692a3, content=<a href='/topic/show?id=834735289ed' target=_blank style='color:#2F92EE;'>#医药创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35289, encryptionId=834735289ed, topicName=医药创新)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Fri Sep 27 07:14:00 CST 2019, time=2019-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285725, encodeId=0ea21285e2576, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Mar 30 16:14:00 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409825, encodeId=7d6e140982531, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Mar 30 16:14:00 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363732, encodeId=097b363e322e, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRkia1DP5MpwEgtXo1XhXA11xD6MWKxunAZFXKSNic0fWHUQx83oNHPlRMxxIctM83QKeCLkJpMibibiaC/0, createdBy=7e581734408, createdName=深海的鱼, createdTime=Fri Mar 29 06:48:25 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363730, encodeId=c6b6363e30b2, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Fri Mar 29 06:09:26 CST 2019, time=2019-03-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1997712, encodeId=345a199e712bd, content=<a href='/topic/show?id=d8d85803457' target=_blank style='color:#2F92EE;'>#新任务#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58034, encryptionId=d8d85803457, topicName=新任务)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c950224, createdName=hjwang79, createdTime=Wed Apr 10 10:14:00 CST 2019, time=2019-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022692, encodeId=a76b2022692a3, content=<a href='/topic/show?id=834735289ed' target=_blank style='color:#2F92EE;'>#医药创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35289, encryptionId=834735289ed, topicName=医药创新)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Fri Sep 27 07:14:00 CST 2019, time=2019-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285725, encodeId=0ea21285e2576, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Mar 30 16:14:00 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409825, encodeId=7d6e140982531, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Mar 30 16:14:00 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363732, encodeId=097b363e322e, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRkia1DP5MpwEgtXo1XhXA11xD6MWKxunAZFXKSNic0fWHUQx83oNHPlRMxxIctM83QKeCLkJpMibibiaC/0, createdBy=7e581734408, createdName=深海的鱼, createdTime=Fri Mar 29 06:48:25 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363730, encodeId=c6b6363e30b2, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Fri Mar 29 06:09:26 CST 2019, time=2019-03-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1997712, encodeId=345a199e712bd, content=<a href='/topic/show?id=d8d85803457' target=_blank style='color:#2F92EE;'>#新任务#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58034, encryptionId=d8d85803457, topicName=新任务)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c950224, createdName=hjwang79, createdTime=Wed Apr 10 10:14:00 CST 2019, time=2019-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022692, encodeId=a76b2022692a3, content=<a href='/topic/show?id=834735289ed' target=_blank style='color:#2F92EE;'>#医药创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35289, encryptionId=834735289ed, topicName=医药创新)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Fri Sep 27 07:14:00 CST 2019, time=2019-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285725, encodeId=0ea21285e2576, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Mar 30 16:14:00 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409825, encodeId=7d6e140982531, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Mar 30 16:14:00 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363732, encodeId=097b363e322e, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRkia1DP5MpwEgtXo1XhXA11xD6MWKxunAZFXKSNic0fWHUQx83oNHPlRMxxIctM83QKeCLkJpMibibiaC/0, createdBy=7e581734408, createdName=深海的鱼, createdTime=Fri Mar 29 06:48:25 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363730, encodeId=c6b6363e30b2, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Fri Mar 29 06:09:26 CST 2019, time=2019-03-29, status=1, ipAttribution=)]
    2019-03-30 cathymary
  5. [GetPortalCommentsPageByObjectIdResponse(id=1997712, encodeId=345a199e712bd, content=<a href='/topic/show?id=d8d85803457' target=_blank style='color:#2F92EE;'>#新任务#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58034, encryptionId=d8d85803457, topicName=新任务)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c950224, createdName=hjwang79, createdTime=Wed Apr 10 10:14:00 CST 2019, time=2019-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022692, encodeId=a76b2022692a3, content=<a href='/topic/show?id=834735289ed' target=_blank style='color:#2F92EE;'>#医药创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35289, encryptionId=834735289ed, topicName=医药创新)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Fri Sep 27 07:14:00 CST 2019, time=2019-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285725, encodeId=0ea21285e2576, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Mar 30 16:14:00 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409825, encodeId=7d6e140982531, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Mar 30 16:14:00 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363732, encodeId=097b363e322e, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRkia1DP5MpwEgtXo1XhXA11xD6MWKxunAZFXKSNic0fWHUQx83oNHPlRMxxIctM83QKeCLkJpMibibiaC/0, createdBy=7e581734408, createdName=深海的鱼, createdTime=Fri Mar 29 06:48:25 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363730, encodeId=c6b6363e30b2, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Fri Mar 29 06:09:26 CST 2019, time=2019-03-29, status=1, ipAttribution=)]
    2019-03-29 深海的鱼

    学习学习学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1997712, encodeId=345a199e712bd, content=<a href='/topic/show?id=d8d85803457' target=_blank style='color:#2F92EE;'>#新任务#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58034, encryptionId=d8d85803457, topicName=新任务)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c950224, createdName=hjwang79, createdTime=Wed Apr 10 10:14:00 CST 2019, time=2019-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022692, encodeId=a76b2022692a3, content=<a href='/topic/show?id=834735289ed' target=_blank style='color:#2F92EE;'>#医药创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35289, encryptionId=834735289ed, topicName=医药创新)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Fri Sep 27 07:14:00 CST 2019, time=2019-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285725, encodeId=0ea21285e2576, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Mar 30 16:14:00 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409825, encodeId=7d6e140982531, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Mar 30 16:14:00 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363732, encodeId=097b363e322e, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRkia1DP5MpwEgtXo1XhXA11xD6MWKxunAZFXKSNic0fWHUQx83oNHPlRMxxIctM83QKeCLkJpMibibiaC/0, createdBy=7e581734408, createdName=深海的鱼, createdTime=Fri Mar 29 06:48:25 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363730, encodeId=c6b6363e30b2, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Fri Mar 29 06:09:26 CST 2019, time=2019-03-29, status=1, ipAttribution=)]

相关资讯

重庆打造儿科医生联盟 将为儿童转诊确定标准

为了让儿童患者在家门口就能享受优质医疗服务,重庆日前以重庆医科大学附属儿童医院为核心,组建儿科医生联盟。该联盟将探索确定儿童双向转诊标准,推动优质儿科医疗资源下沉。重庆医科大学附属儿童医院科研处副处长赵耀告诉记者,组建儿科医生联盟的目的,是逐步探索建立一套相对完善、明晰的儿童转诊标准,推动建立大型医疗设备共享和检查结果互认等相关制度,使小病真正能在基层治疗,而急危重病患者能及时、畅通地转诊到上级

重庆实施“智慧医疗”优先行动

近日,重庆市卫生计生委印发《“智慧医疗”优先行动实施方案(2018—2020年)》提出, 到2020年,实现三级医院“智慧医院”示范建设全覆盖,所有二级以上医院开展远程医疗服务,逐步构建标准规范、智能精准、开放共享、公平高效的智慧医疗和健康信息服务体系。

重庆推复合式医保支付方式

近日,重庆市政府网发布《重庆市进一步深化基本医疗保险支付方式改革实施方案》。

勒是雾都!看改善医疗服务之重庆范本

以江城着称、以山城扬名,是重庆这座城市最显着的特点。慢是生活基调,而与之形成鲜明反差的是就医速率的“快”;依山傍水是城市风貌,与之相呼应的是医院建设在力求美丽。于改善医疗服务的方方面面,重庆始终在行动。就医体验UP UP UP重庆市卫生计生委将改善医疗服务作为重点工作,并与深化医药卫生体制改革的各项工作统筹协调、同步推进,提出了改善医疗服务的“1+3”行动计划,即1套行动方案+3个专项行动——

涉嫌骗取医疗保障基金 重庆213家定点机构暂停结算

11月23日,重庆市医疗保障局发布消息,年底前重庆将集中实施打击欺诈骗取医疗保障基金专项行动。截至到10月底,因为医保结算违规,全市有213家定点医疗机构和定点药店暂停结算和解除定点协议,另外有5个骗保案件移送公安机关。首次集中打击医保乱象据悉,这是重庆市医疗保障局组建以来,首次集中打击欺诈骗取医疗保障基金专项行动,行动组建了6个专项检查组。重点检查有案不查/查处不力和举报投诉问题较多的区县,重

重庆:医生处方少用集中采购药 将被约谈

为落实第一批国家组织“4+7”药品集中采购,3月5日,国家医保局正式下发了《关于国家组织药品集中采购和使用试点医保配套措施的意见》(医保发〔2019〕18号)(以下简称“意见”),要求包括重庆在内的“4+7”城市所在医保局,在医保基金预算中明确国家组织药品集中采购和使用试点药品专项采购预算,并规定对未完成采购量的医疗机构,扣减次年度医保费用,对中选品种处方量下降明显的医生进行约谈。支付标准将在2—